“Electromed delivered record-breaking sales, earnings, and cash generation under a new leadership team, causing the stock to soar by 176%. The company's SmartVest device continues to take market share within the growing bronchiectasis treatment market.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
